Variations in the APOA1 gene can alter the efficacy of fenofibrate, a fibric acid derivative aimed at reducing cholesterol and triglycerides. This interaction occurs as fenofibrate influences lipoprotein lipase activity and VLDL levels, which in turn affects the APOA1-mediated reverse cholesterol transport essential for cardiovascular health.